TD Asset Management Inc Acquires 118,886 Shares of Guardant Health, Inc. $GH

TD Asset Management Inc increased its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 272.0% during the 2nd quarter, HoldingsChannel reports. The fund owned 162,600 shares of the company’s stock after buying an additional 118,886 shares during the period. TD Asset Management Inc’s holdings in Guardant Health were worth $8,462,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Signaturefd LLC lifted its stake in shares of Guardant Health by 50.5% in the second quarter. Signaturefd LLC now owns 635 shares of the company’s stock worth $33,000 after buying an additional 213 shares in the last quarter. IFP Advisors Inc lifted its stake in shares of Guardant Health by 120.1% in the second quarter. IFP Advisors Inc now owns 612 shares of the company’s stock worth $33,000 after buying an additional 334 shares in the last quarter. SVB Wealth LLC bought a new position in shares of Guardant Health in the first quarter worth approximately $54,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Guardant Health in the first quarter worth approximately $97,000. Finally, CWM LLC lifted its stake in shares of Guardant Health by 180.3% in the first quarter. CWM LLC now owns 2,296 shares of the company’s stock worth $98,000 after buying an additional 1,477 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

GH has been the topic of a number of research analyst reports. Mizuho increased their price objective on shares of Guardant Health from $65.00 to $70.00 and gave the company an “outperform” rating in a research report on Thursday, September 25th. Stifel Nicolaus set a $73.00 price objective on shares of Guardant Health in a research report on Thursday, September 25th. Wolfe Research upgraded shares of Guardant Health from a “peer perform” rating to an “outperform” rating and set a $75.00 price objective on the stock in a research report on Thursday, September 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Guardant Health in a research report on Wednesday, October 8th. Finally, Wells Fargo & Company began coverage on shares of Guardant Health in a research report on Monday, September 22nd. They issued an “overweight” rating and a $72.00 price target on the stock. Twenty-three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $65.86.

Insider Buying and Selling at Guardant Health

In other news, CEO Helmy Eltoukhy sold 300,000 shares of the firm’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $59.45, for a total transaction of $17,835,000.00. Following the sale, the chief executive officer directly owned 2,123,499 shares in the company, valued at $126,242,015.55. This trade represents a 12.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Medina Manuel Hidalgo sold 2,165 shares of the firm’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $54.16, for a total transaction of $117,256.40. Following the sale, the director owned 851 shares in the company, valued at $46,090.16. The trade was a 71.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 302,549 shares of company stock worth $17,975,121 over the last 90 days. Insiders own 6.10% of the company’s stock.

Guardant Health Stock Performance

Shares of Guardant Health stock opened at $65.46 on Monday. Guardant Health, Inc. has a one year low of $20.14 and a one year high of $68.23. The stock’s fifty day moving average is $61.06 and its 200 day moving average is $50.96. The stock has a market cap of $8.16 billion, a P/E ratio of -19.54 and a beta of 1.53.

Guardant Health (NASDAQ:GH) last announced its earnings results on Wednesday, July 30th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.08. The company had revenue of $232.09 million during the quarter, compared to the consensus estimate of $211.19 million. Guardant Health’s revenue for the quarter was up 31.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.84) earnings per share. Guardant Health has set its FY 2025 guidance at EPS. Analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.